Evidence map›Paper›PMID 42111058›Full record

ArticlePhysics and imaging in radiation oncology2026

Trends in brachytherapy utilization in Canada from 2011 to 2020.

Mirta Dumančić, Yujing Zou, Harry Glickman, Sara Ghassimi Kouraneh, Piotr Pater, Andrew Alexander, Jorge E Alpuche Aviles, Amanda Cherpak, Kristin Marchant, Geetha Menon and 6 more

Abstract read
In one paragraph

Article in Physics and imaging in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Mirta DumančićMedical Physics Unit, Department of Oncology, Faculty of Medicine, McGill University, Montréal, QC, Canada.
Yujing ZouMedical Physics Unit, Department of Oncology, Faculty of Medicine, McGill University, Montréal, QC, Canada.
Harry GlickmanMedical Physics Unit, Department of Oncology, Faculty of Medicine, McGill University, Montréal, QC, Canada.
Sara Ghassimi KouranehFaculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada.
Piotr PaterMedical Physics Unit, Department of Oncology, Faculty of Medicine, McGill University, Montréal, QC, Canada.
Andrew AlexanderDepartment of Radiation Oncology, Queen Elizabeth Hospital, Prince Edward Island Cancer Treatment Centre, Charlottetown, PEI, Canada.
Jorge E Alpuche AvilesDepartment of Radiology and Physics & Astronomy, University of Manitoba, Winnipeg, MB, Canada.
Amanda CherpakDepartment of Medical Physics, QEII Health Sciences Centre, Halifax, NS, Canada.
Kristin MarchantAllan Blair Cancer Centre, Department of Medical Physics, Regina, SK, Canada.
Geetha MenonDepartment of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada.
Daniel MortonSaskatoon Cancer Centre, Department of Medical Physics, Saskatoon, SK, Canada.
Tim OldingMedical Physics, Kingston Health Sciences Centre, Kingston, ON, Canada.
Moti PaudelDepartment of Medical Physics, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Alexandra RinkDepartment of Radiation Oncology, University of Toronto, Toronto, ON, Canada.
Ingrid SpadingerBC Cancer (Vancouver), Department of Medical Physics, Vancouver, BC, Canada.
Shirin A EngerMedical Physics Unit, Department of Oncology, Faculty of Medicine, McGill University, Montréal, QC, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Purpose: Brachytherapy is a highly conformal and cost-effective radiotherapy modality, yet its clinical utilization has declined in multiple regions. This study investigated trends in brachytherapy utilization across different Canadian provinces from 2011 to 2020. Materials and Methods: A national survey was distributed to medical physicists in cancer centres across ten Canadian provinces, collecting data on types of brachytherapy, annual number of treatments, clinical indications, and logistical factors. In Québec, treated clinical indications were obtained through a complementary survey of all radiotherapy centres, extending previously published provincial brachytherapy data. Results: Out of 39 radiotherapy centres in Canada conducting brachytherapy treatments, 25 centres were included in this study. HDR accounted for the majority of treatments (60%-100%) and increased in most provinces, while LDR declined across reporting provinces; PDR comprised Conclusions: This study revealed significant regional variations in brachytherapy utilization and clinical practices across Canadian radiotherapy centres. Factors influencing these trends include reimbursement structures, personnel and infrastructure availability, and clinician preferences. The use of HDR modalities is increasing nationally, while LDR is declining. Despite significant regional differences, brachytherapy utilization in Canada was largely sustained over the decade from 2011 to 2020.

Indexed as

Brachytherapy utilizationCanadaHealthcare policyHigh-dose-rateLow-dose-rateRadiation oncology

Identifiers

PMID42111058
PMCPMC13157207

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.